Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Lancet Respir Med ; 12(7): 556-574, 2024 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-38677306

RESUMEN

Indigenous peoples around the world bear a disproportionate burden of chronic respiratory diseases, which are associated with increased risks of morbidity and mortality. Despite the imperative to address global inequity, research focused on strengthening respiratory health in Indigenous peoples is lacking, particularly in low-income and middle-income countries. Drivers of the increased rates and severity of chronic respiratory diseases in Indigenous peoples include a high prevalence of risk factors (eg, prematurity, low birthweight, poor nutrition, air pollution, high burden of infections, and poverty) and poor access to appropriate diagnosis and care, which might be linked to colonisation and historical and current systemic racism. Efforts to tackle this disproportionate burden of chronic respiratory diseases must include both global approaches to address contributing factors, including decolonisation of health care and research, and local approaches, co-designed with Indigenous people, to ensure the provision of culturally strengthened care with more equitable prioritisation of resources. Here, we review evidence on the burden of chronic respiratory diseases in Indigenous peoples globally, summarise factors that underlie health disparities between Indigenous and non-Indigenous people, propose a framework of approaches to improve the respiratory health of Indigenous peoples, and outline future directions for clinical care and research.


Asunto(s)
Pueblos Indígenas , Humanos , Enfermedad Crónica/terapia , Enfermedad Crónica/etnología , Salud Global , Disparidades en Atención de Salud/etnología , Enfermedades Respiratorias/terapia , Enfermedades Respiratorias/etnología , Enfermedades Respiratorias/epidemiología , Servicios de Salud del Indígena/organización & administración , Disparidades en el Estado de Salud , Factores de Riesgo , Inequidades en Salud
2.
Pediatr Pulmonol ; 58(11): 3195-3205, 2023 11.
Artículo en Inglés | MEDLINE | ID: mdl-37589420

RESUMEN

INTRODUCTION: The association between viral infections and pulmonary exacerbations in children with cystic fibrosis (cwCF) is well established. However, the question of whether cwCF are at a higher risk of COVID-19 or its adverse consequences remains controversial. METHODS: We conducted an observational, multicenter, cross-sectional study of cwCF infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) between March 2020 and June 2022, (first to sixth COVID-19 pandemic waves) in Spain. The study aimed to describe patients' basal characteristics, SARS-CoV-2 clinical manifestations and outcomes, and whether there were differences across the pandemic waves. RESULTS: During study time, 351 SARS-CoV2 infections were reported among 341 cwCF. Median age was 8.5 years (range 0-17) and 51% were female. Cases were unevenly distributed across the pandemic, with most cases (82%) clustered between November 2021 and June 2022 (sixth wave, also known as Omicron Wave due to the higher prevalence of this strain in that period in Spain). Most cwCF were asymptomatic (24.8%) or presented with mild Covid-19 symptoms (72.9%). Among symptomatic, most prevalent symptoms were fever (62%) and increased cough (53%). Infection occurring along the sixth wave was the only independent risk factor for being symptomatic. Just eight cwCF needed hospital admission. No multisystem inflammatory syndrome, persisting symptoms, long-term sequelae, or deaths were reported. CONCLUSIONS: Spanish current data indicate that cwCF do not experience higher risks of SARS-CoV-2 infection nor worse health outcomes or sequelae. Changes in patients' basal characteristics, clinical courses, and outcomes were detected across waves. While the pandemic continues, a worldwide monitoring of COVID-19 in pediatric CF patients is needed.


Asunto(s)
COVID-19 , Fibrosis Quística , Humanos , Niño , Femenino , Recién Nacido , Lactante , Preescolar , Adolescente , Masculino , COVID-19/complicaciones , COVID-19/epidemiología , SARS-CoV-2 , Estudios Transversales , España/epidemiología , Pandemias , Fibrosis Quística/complicaciones , Fibrosis Quística/epidemiología , ARN Viral
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...